Loading stock data…
$13.77-0.01 (-0.04%)
Organon & Co.
Organon & Co. in the Healthcare sector is trading at $13.77 with a market capitalization of $3.6B. Wall Street consensus targets $11.25 (4 analysts), implying a -18.3% move over the next 12 months. The stock is currently near its 52-week high of $13.83, remaining 23.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.56B↑ | $1.46B↓ | $1.51B↓ | $1.60B↑ | $1.59B |
| Gross Profit | $847.00M↑ | $783.00M↑ | $741.00M↓ | $857.00M↓ | $874.00M |
| Operating Income | $323.00M↑ | $266.00M↑ | $217.00M↓ | $358.00M↑ | $326.00M |
| Net Income | $108.00M↓ | $146.00M↑ | -$205.00M↓ | $160.00M↑ | $145.00M |
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internatio...